Literature DB >> 19660777

[Mechanisms of deregulated response to hypoxia in sporadic amyotrophic lateral sclerosis: a clinical study].

C Moreau1, D Devos, P Gosset, V Brunaud-Danel, A-B Tonnel, P Lassalle, L Defebvre, A Destée.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motorneurons, leading to death in 3 to 5 years. Respiratory insufficiency and hypoxemia are closely linked during the clinical course of ALS. Chronic respiratory insufficiency and hypoxemia generally occur late in the disease course but rapid episodes of intermittent hypoxemia followed by reoxygenation can occur early and insidiously. Two pathways are involved in the response to hypoxemia: (i) hypoxia inducible factor-1 (HIF-1) and VEGF/HIF-2 and an erythropoietin (EPO) mediated pathway, in response to prolonged hypoxemia; and (ii) nuclear factor kappa-B (NFkappa-B) during acute hypoxemia followed by reoxygenation episodes, inducing inflammatory mediators: interleukin-6 (IL-6), TNF-alpha, cyclo oxygenase-2 (COX-2) and prostaglandin E-2 (PGE-2). Our aim was to specify the role of the different functional pathways of response to hypoxemia in sporadic ALS patients, compared with neurological controls and according to the level of hypoxemia. We report the results of several studies of hypoxemic and/or inflammatory mediators in the cerebrospinal fluid (CSF) from ALS patients, according to their respiratory status, showing a selective defect of HIF-1 mediated angiogenic factors (VEGF and angiogenin [ANG]) during chronic hypoxia in sporadic ALS patients, compared to hypoxemic neurological controls; contrasting with an early activation of the NFkappa-B pathway since the isolated desaturation stage (IL-6, TNF-alpha, PGE-2, angiopoietin-2) in the same cohort of sporadic ALS patients. All these results are consistent with a selective impairment of the HIF-1 pathway during chronic hypoxemia in ALS patients. Inflammatory mediators were strongly elevated, since the early stage of the disease until chronic hypoxemia, suggesting a compensatory mechanism. Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19660777     DOI: 10.1016/j.neurol.2009.05.018

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  5 in total

1.  Spinal vascular endothelial growth factor induces phrenic motor facilitation via extracellular signal-regulated kinase and Akt signaling.

Authors:  Erica A Dale-Nagle; Irawan Satriotomo; Gordon S Mitchell
Journal:  J Neurosci       Date:  2011-05-25       Impact factor: 6.167

2.  Serum biomarkers of neuroinflammation and blood-brain barrier leakage in amyotrophic lateral sclerosis.

Authors:  Maize C Cao; Erin E Cawston; Grace Chen; Collin Brooks; Jeroen Douwes; Dave McLean; E Scott Graham; Mike Dragunow; Emma L Scotter
Journal:  BMC Neurol       Date:  2022-06-11       Impact factor: 2.903

Review 3.  Advances in cellular models to explore the pathophysiology of amyotrophic lateral sclerosis.

Authors:  C Veyrat-Durebex; P Corcia; A Dangoumau; F Laumonnier; E Piver; P H Gordon; C R Andres; P Vourc'h; H Blasco
Journal:  Mol Neurobiol       Date:  2013-11-07       Impact factor: 5.590

4.  Patient-derived olfactory mucosa for study of the non-neuronal contribution to amyotrophic lateral sclerosis pathology.

Authors:  Vega García-Escudero; María Rosales; José Luis Muñoz; Esteban Scola; Javier Medina; Hena Khalique; Guillermo Garaulet; Antonio Rodriguez; Filip Lim
Journal:  J Cell Mol Med       Date:  2015-03-25       Impact factor: 5.310

Review 5.  Ventilatory Dysfunction in Parkinson's Disease.

Authors:  Guillaume Baille; Anna Maria De Jesus; Thierry Perez; David Devos; Kathy Dujardin; Christelle Monaca Charley; Luc Defebvre; Caroline Moreau
Journal:  J Parkinsons Dis       Date:  2016-06-16       Impact factor: 5.568

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.